Global Pompe Disease Treatment Market: Industry Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015-2020 and Forecast 2021-2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Pompe Disease Treatment Market: By Treatment Type (Enzyme Replacement Therapy, Gene Therapy), By Age Group Type (infantile-Onset Pompe Disease, Late Onset Pompe Disease), and Geography.

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Global Pompe Disease Treatment Market is expected to register a CAGR of 3.8% during the forecast period of 2021 to 2027 and was valued at US$ 1099.1 Mn in 2020. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). For instance, according to a research study, approximately 5000 to 10,000 people are affected with pompe disease around the world. Moreover, rise in R&D for the development of newer products, strong product pipeline, and raise in funding from public and private sectors are expected to propel the market over the forecast years.Increase in the R&D for the development of newer therapeutics is a major factor drive the global pompe disease treatment market over the forecast years. Pompe illness is a genetic metabolic ailment that affects babies and is caused by mutations in the GAA gene, which produces the acid alpha-glucosidase enzyme, which reduces glycogen to a simple form. The lack or mutation of the GAA gene causes glycogen buildup, which causes heart problems, muscle weakness, and liver damage, which can lead to early death.

Pompe Disease Treatment Market

MARKET SUMMARY
-
3.8%
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 3.8%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Pompe Disease Treatment Market

  • Global pompe disease treatment market report gives comprehensive outlook on pompe disease treatment across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report gives historical, current, and future market sizes (US$ Mn) on the basis of treatment type, age group, and region.
  • Key stakeholders of the market include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global pompe disease treatment products.
Market Key Players
  • Valerion Therapeutics
  • Actus Therapeutics, Inc.
  • BioMarin Pharmaceutical
  • Audentes Therapeutics
  • Amicus Therapeutics
  • Sanofi Genozyme
  • Greenovation Biotech GmbH
Drivers

Pompe Disease Treatment Market

According to the National Organization for Rare Disorders, Pompe disease affects about one out of every 40,000 persons in the United States. The Pompe Disease Market is being driven by an increase in manufacturers focusing on growing their pipeline to meet the demand for Pompe condition therapy as the prevalence of the disease rises.


North-America Got Significant Share

Pompe Disease Treatment Market

North America accounted for larger revenue share in global market by 2027 owing to increase in the prevalence of disease in USA and Canada. For instance, according to National Organization for Rare Disorders, pompe disease incidence is generally placed at approximately 1 in 40,000 births in the United States. Moreover, Europe pompe disease treatment market contributed highest growth rate in 2020 and expected to grow at 9.10% CAGR over the forecast years owing to increase in research and development on newer procedures, and favorable reimbursement policies in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Findings of the Report

  • Global pompe disease treatment market expanding at significant CAGR over 2021 to 2027 owing to increase in the prevalence of pompe disease.
  • Based on treatment, enzyme replacement therapy accounted for larger market revenue share in 2020 and projected gain market revenue share over the forecast period
  • Players focusing on innovation of newer products and collaboration strategies to retain market position in global pompe disease treatment market

Key

Key Features of the Report

Pompe Disease Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Valerion Therapeutics
  • Actus Therapeutics, Inc.
  • BioMarin Pharmaceutical
  • Audentes Therapeutics
  • Amicus Therapeutics
  • Sanofi Genozyme
  • Greenovation Biotech GmbH

Description

Global Pompe Disease Treatment Market is expected to register a CAGR of 3.8% during the forecast period of 2021 to 2027 and was valued at US$ 1099.1 Mn in 2020. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). For instance, according to a research study, approximately 5000 to 10,000 people are affected with pompe disease around the world. Moreover, rise in R&D for the development of newer products, strong product pipeline, and raise in funding from public and private sectors are expected to propel the market over the forecast years.Increase in the R&D for the development of newer therapeutics is a major factor drive the global pompe disease treatment market over the forecast years. Pompe illness is a genetic metabolic ailment that affects babies and is caused by mutations in the GAA gene, which produces the acid alpha-glucosidase enzyme, which reduces glycogen to a simple form. The lack or mutation of the GAA gene causes glycogen buildup, which causes heart problems, muscle weakness, and liver damage, which can lead to early death.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX